Accession Number: | 0001104659-20-071838 |
Date: | 2020-06-10 |
Issuer: | STEMLINE THERAPEUTICS INC (STML) |
Original Submission Date: |
HUME DANIEL
C/O STEMLINE THERAPEUTICS, INC.
750 LEXINGTON AVENUE, ELEVENTH FLOOR
NEW YORK, NY 10022
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2020-06-10 | U | 35,468 | d | $0.00 | 0 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|
ID | footnote |
---|---|
f1 | disposed of in connection with a tender offer made pursuant to an agreement and plan of merger among issuer, berlin-chemie ag, and mercury merger sub, inc., dated as of may 3, 2020, in exchange for $11.50 per share, net to the holder in cash, plus one contractual contingent value right ("cvr") per share. each cvr represents the right to receive a payment of $1.00 in cash upon the achievement of a certain milestone relating to the first sale of elzonris in any one of certain countries following a marketing authorization approval by the european commission. the cvr milestone must be achieved on or prior to december 31, 2021. |